NeoImmuneTech announces small third-party allotment for North American rights to Endari, dilution limited to 2% and issuance at premium protects shareholder value
NeoImmuneTech conducted a third-party allotment to raise 1.5 billion KRW for acquiring North American rights to the sickle cell disease treatment Endari.
The new shares amount to 683,960 shares representing a dilution of approximately 2% relative to outstanding shares, and the issuance price reflects a premium over the current market price, limiting shareholder value dilution.
The counterparty is Mmos Life Sciences, which has negative equity, posing a credit risk despite the small scale of the transaction.
New shares are subject to a one-year lock-up period, restricting short-term selling pressure.
[AI Summary]NeoImmuneTech raised funds for Endari North American rights through a small third-party allotment. Dilution is low at 2% and the premium issuance protects shareholder value, but the counterparty's weak financials introduce credit risk. The success of the fund usage will influence stock price volatility.
KOSDAQ Filing Information
Securities Issuance Result (Voluntary Disclosure) (Third-Party Allotment Rights Offering)